We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+23.12%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$182M
AUM Growth
-$10.6M
Cap. Flow
-$3.56M
Cap. Flow %
-1.95%
Top 10 Hldgs %
100%
Holding
12
New
1
Increased
2
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
LJPC
La Jolla Pharmaceutical Company
LJPC
+$2.76M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$2.38M
3
ACHV icon
Achieve Life Sciences
ACHV
+$811K

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$843K
2
PHIO icon
Phio Pharmaceuticals
PHIO
+$100K
3
DNDN
DENDREON CORPORATION
DNDN
+$80K

Sector Composition

Rank Sector Weight
1 Healthcare 64.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$86.3M
$49.5M 27.14%
4,919,625
– –
LJPC
2
DELISTED
La Jolla Pharmaceutical Company
LJPC
$39.6M 21.69%
2,144,387
+232,925
+12% +$2.76M
SLXP
3
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$34.5M 18.91%
300,000
– –
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.5B
$16.5M 9.04%
182,300
– –
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.32M 3.46%
490,000
+190,000
+63% +$2.38M
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.42M 2.42%
238,432
-50,000
-17% -$843K
ACHV icon
7
Achieve Life Sciences
ACHV
$626M
$836K 0.46%
+166
New +$811K
PHIO icon
8
Phio Pharmaceuticals
PHIO
$12.1M
– –
0
– -$100K
DNDN
9
DELISTED
DENDREON CORPORATION
DNDN
– –
-55,548
Closed -$80K
AMBI
10
DELISTED
Ambit Biosciences Corp
AMBI
– –
-46
Closed –

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $1.98B AUM 1.62% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Tang Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Tang Capital Management held 12 positions worth $182M, down 5.5% from $193M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Tang Capital Management's Q4 2014 filing shows 1 new, 2 increased, 1 reduced and 2 closed positions. Its largest new stake was Achieve Life Sciences: 166 shares worth $836K. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $843K.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 42% a quarter earlier.

  • Tang Capital Management's largest Q4 2014 buy was Achieve Life Sciences: 166 shares worth $836K.
  • Tang Capital Management added most to La Jolla Pharmaceutical Company in Q4 2014, an estimated $2.76M increase.
  • Tang Capital Management's biggest Q4 2014 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $843K.
  • Tang Capital Management fully exited DENDREON CORPORATION in Q4 2014, selling an estimated $80K.
  • Tang Capital Management's ten largest holdings make up 100% of its $182M portfolio in Q4 2014.
  • Tang Capital Management opened 1 new position and closed 2 in Q4 2014.
  • Tang Capital Management's portfolio value fell 5.5% quarter-over-quarter to $182M.

Based on Tang Capital Management's 13F filing for Q4 2014, filed 27 Jan 2015.